Integrated Training in Pharmacological Sciences

项目摘要 这是西奈山伊坎医学院培训项目的更新申请， 在它的第17个年头。在以前的项目期间，我们开发了一个创新的药理学项目， 科学，帮助建立西奈山作为一个领导者在新生领域的系统 药理学我们是为所有博士引入定量和计算培训的早期倡导者 生物医学科学的候选人，这仍然是我们课程的基石原则。在课程中， 学生通过解决问题和主动学习练习应用定量/计算方法， 药物发现和药物作用的基本生物学概念在一个 促进参与的疾病背景。除了严格和创新的课程，学员在 我们的计划受益于提高研究经验的活动，包括期刊俱乐部， 进展研讨会，专注于职业发展的年度务虚会，以及年度系统药理学 研讨会提供了网络机会。下一个项目期间将在这些成功的基础上再接再厉 并引入新的举措，包括翻转课堂，以最大限度地提高学员的灵活性，一个新的课程， 由制药行业的科学家共同授课，并为所有项目导师提供正式培训。 对于论文研究，学员可以由42位资金充足的研究人员中的任何一位指导，这些研究人员具有以下方面的专业知识： 在药理学的不同领域，如基于结构的药物设计，数学建模， 病理生理学和药物作用，以及生物工程。学生解决前沿问题，必须是 解决了在疾病领域如癌症，心血管疾病， 神经系统疾病、糖尿病以及肾脏和肝脏疾病。这种结构已被证明是非常有效的， 培养成功的年轻科学家。在过去10年中完成该计划的受训人员 平均在5.1年内完成博士学位，通常总共发表了近5篇论文 （平均4.88）和超过2篇第一作者出版物（平均2.2），这是他们在芒特训练期间发表的 西奈计划校友已经成功的职业生涯，共同解决了许多方面的问题， 药理学，无论是在学术界还是在制药行业。我们的目标是继续 创新和发展学员谁将成为明天的领导者在药理学和解决紧迫的 药物开发需要新的方法。

PROJECT SUMMARY This is a renewal application of a training program at Icahn School of Medicine at Mount Sinai that is currently in its 17th year. In previous project periods, we have developed an innovative program in pharmacological sciences that has helped to establish Mount Sinai as one of the leaders in the nascent field of systems pharmacology. We were early advocates of introducing quantitative and computational training for all PhD candidates in biomedical sciences, and this remains the cornerstone principle of our curriculum. In coursework, students apply quantitative/computational approaches through problem solving and active learning exercises, and fundamental biological concepts underlying drug discovery and drug action are communicated within a disease context that promotes engagement. In addition to the rigorous and innovative curriculum, trainees in our program benefit from activities that enhance the research experience, including journal clubs, Works-in- Progress seminars, an annual retreat focused on career development, and an annual systems pharmacology symposium that provides networking opportunities. The coming project period will build on these successes and introduce new initiatives including flipped classrooms to maximize trainee flexibility, a new course that will be co-taught by pharmaceutical industry scientists, and formal training for all program mentors. For dissertation research, trainees can be mentored by any of 42 well-funded investigators with expertise in approaches in varied areas of pharmacology such as structure-based drug design, mathematical modeling of pathophysiology and drug action, and bioengineering. Students address cutting edge issues that must be solved to develop safe and effective therapeutics in disease areas such as cancer, cardiovascular disease, neurological disorders, diabetes, and kidney and liver disease. This structure has proven highly effective at producing successful young scientists. Trainees who have completed the program during the past 10 years have finished their PhDs in an average of 5.1 years and have typically produced nearly 5 total publications (average 4.88) and over 2 first author publications (average 2.2) resulting from their time in training at Mount Sinai. Program alumni have gone on to successful careers that collectively address many aspects of pharmacological sciences, both in academia and in the pharmaceutical industry. We aim to continue to innovate and develop trainees who will become tomorrow’s leaders in pharmacology and address the urgent need for new approaches in drug development.